WHO vaccine-preventable diseases: monitoring system. 2016 global summary

Last updated 1-December 2016 (data as of 18-November-2016)
Next overall update June 2017
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 84'1801 Infant (under 12 months) mortality rate: 02
GDP / capita (US$): 60'5351 Child (under 5 years) mortality rate: 02

Population data in thousands3

  2015  2014  2013  2012  2011  2000  1990  1980 
Total population 8'299  8'211  8'119  8'023  7'926  7'166  6'674  6'304 
Births 86  85  83  82  81  76  81  73 
Surviving infants 86  84  83  82  80  76  80  72 
Pop. less than 5 years 423  416  410  403  395  401  385  356 
Pop. less than 15 years 1'226  1'212  1'201  1'192  1'186  1'250  1'137  1'261 
Female 15-49 years 1'933  1'932  1'928  1'920  1'909  1'766  1'719  1'587 

Number of reported cases

(Click for retrospective incidence data for Switzerland)
Diphtheria
ChartChart
 
Japanese encephalitis
ChartChart
 
Measles
ChartChart ChartChart
  35  23  175  61  621  1'990 
Mumps
ChartChart
  140 
Pertussis
ChartChart
  4'700 
Polio*
ChartChart
 
Rubella
ChartChart
  10 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
ChartChart
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Switzerland)
Vaccine year result method % card seen                                                
BCG         
DTP1          95  95 
DTP3          97  96  96  96  96  93  90 
DTP4          91  89 
IPV1         
HepB_BD         
HepB3          17  16 
Hib3          97  95  95  95  95  91 
JapEnc         
MCV1          94  93  93  93  93  82  90 
MCV2          89  87  86  86  86 
PCV1          85  84  79 
PCV3          81  80  75  75  75 
Pol3          97  96  96  96  96  95  98 
Rota1         
RotaC         
RCV1          94  93  91  91 
TT2plus         
PAB         
VAD1         
YFV         
° indicates that more than 1 survey occurred that year.  * indicates the country reported above 100% coverage.

  Next update: Mid July 2017

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Switzerland)
DTP1
ChartChart
  99  98  98  98  98  95  96 
DTP3
ChartChart
  97  96  96  96  96  93  90 
HepB3
ChartChart
 
HepB_BD
ChartChart
 
Hib3
ChartChart
  97  95  95  95  95  91 
MCV1
ChartChart
  94  93  93  93  93  82  90 
MCV2
ChartChart
  89  87  86  86  86 
PCV3
ChartChart
  81  80  75  62  50 
Pol3
ChartChart
  97  96  96  96  96  95  98 
RCV1
ChartChart
  94  93  93  93  93  82  90 
RotaC
ChartChart
 

Number of districts in the country 26  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2015 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes going to high-prevalence countries before age 1 year
DTaPHibIPV 2, 4, 6, 15-24 months; Yes
DTaPIPV 4-7 years; Yes
HPV 11-14 years; +6 months; Yes
HepB_Adult 11-15 years; +6 months; Yes and risk groups
HepB_Pediatric birth; 1, 6, 15-24months; Yes Infants of HBsAg+ mothers
Influenza_Adult >= 65 years; Yes and adults with chronic diseases, pregnant women, health care workers, Haj and travelers and other risk groups
Influenza_Pediatric Yes children with chronic diseases
MMR 12, 15-24 months; Yes
MenACWY Yes risk groups
MenC_conj 12 months; 11-15 years; Yes supplementary
Pneumo_conj 2, 4, 12 months; Yes or 2, 4, 6, 12 months for risk groups
Pneumo_ps >= 65 years; Yes
Td 45, 65 years; Yes + every 10 years thereafter
Tdap 11-15, 25-29 years; Yes and person in contact with infants < 6 months
Varicella 11-15 years; Yes no anamnestic disease

Immunizaton indicators

Indicator Expected answer 2015  2014  2013  2012  2011  2010  2009 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  No  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number     2012-2015  2012-2015       
Nº of districts with microplans that include activities to raise immunization coverage number              

System performance

Total Nº districts in country number 26  26      26  26  26 
Nº districts with DTP3 coverage >=80% number          
% of districts with DTP3 coverage >=80% From 0 to 100%              
Nº districts with measles (MCV1) coverage >=95% number        
% of districts with MCV1 coverage >=95% From 0 to 100%            

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes    Yes  Yes  Yes  Yes   
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%    

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes   

Sources

 1  "The 2016 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2015
 3  "United Nations, Population Division. The World Population Prospects - the 2015 revision". New York, 2016.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.